Bona fide gift to Sergio Traversa of 4131 shares of Relmada Therapeutics subject to Section 16

RLMD Stock  USD 3.02  0.12  4.14%   
About 71 percent of all Relmada Therapeutics' shareholders are curious in acquiring. The analysis of overall sentiment of trading Relmada Therapeutics stock suggests that quite a large number of investors are confidant at this time. The current market sentiment, together with Relmada Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Relmada Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Relmada Therapeutics Inc director. Exempt bona fide gift subject to Rule 16b-3

Read at macroaxis.com
Relmada insider trading alert for gift of stock option right to buy by Sergio Traversa, CEO, on 6th of February 2023. This event was filed by Relmada Therapeutics Inc with SEC on 2023-02-06. Annual statement of changes in beneficial ownership - SEC Form 5

Cash Flow Correlation

Relmada Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Relmada Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Relmada Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Relmada Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Relmada Therapeutics Fundamental Analysis

We analyze Relmada Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relmada Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relmada Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Liabilities

Current Liabilities Comparative Analysis

Relmada Therapeutics is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Relmada Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Relmada Therapeutics stock to make a market-neutral strategy. Peer analysis of Relmada Therapeutics could also be used in its relative valuation, which is a method of valuing Relmada Therapeutics by comparing valuation metrics with similar companies.

Peers

Relmada Therapeutics Related Equities

IPSCCentury Therapeutics   5.52   
0%
100.0%
CSBRChampions Oncology   4.87   
0%
88.0%
EWTXEdgewise Therapeutics   2.48   
0%
44.0%
RAPTRAPT Therapeutics   2.44   
0%
44.0%
PMVPPmv Pharmaceuticals   1.25   
0%
22.0%
STTKShattuck Labs   0.92   
0%
16.0%
NUVBNuvation Bio   0.35   
0%
6.0%
BCYCBicycle Therapeutics   0.25   
0%
4.0%
CYTKCytokinetics   0.69   
12.0%
0%
RVMDRevolution Medicines   1.25   
22.0%
0%
ELYMEliem Therapeutics   1.30   
23.0%
0%
DYNDyne Therapeutics   1.67   
30.0%
0%
THRDThird Harmonic   2.67   
48.0%
0%
NAMSNewAmsterdam Pharma   4.57   
82.0%
0%

Complementary Tools for Relmada Stock analysis

When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
CEOs Directory
Screen CEOs from public companies around the world
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios